尊龙凯时人生就是搏·(中国区)官方网站
About Us
About Sino Biopharm
Board of Directors
Senior Management
R&D
R&D Team
Products
Product List
Sustainability
ESG Governance
ESG Management Practices
ESG Reports
Investors
Information Disclosure
Corporate Governance
Presentation
Investor FAQ
Notices
News
Press Releases
Contact
CN
EN
Investors
Home
>
Investors
>
Information Disclosure
Information Disclosure
Corporate Governance
Presentation
Investor FAQ
Notices
Information Disclosure
VOLUNTARY ANNOUNCEMENT
2025.06.10
AMENDED AND RESTATED ARTICLES OF ASSOCIATION
2025.06.10
VOLUNTARY ANNOUNCEMENT - TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR" OBTAINING APPROVAL FOR PHASE III REGISTRATIONAL CLINICAL STUDY FROM CDE
2025.06.09
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART WITH OR WITHOUT ANLOTINIB AS MAINTENANCE TREATMENT FOR NON-SMALL CELL LUNG CANCER WITHOUT PROGRESSION FOLLOWING CHEMORADIOTHERAPY PRESENTED AT 2025 ASCO ANNUAL MEETING
2025.06.05
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER PRESENTED AT 2025 ASCO ANNUAL MEETING
2025.06.03
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2025
2025.06.02
VOLUNTARY ANNOUNCEMENT
2025.05.29
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I STUDY OF TQB2102 (BISPECIFIC ANTI-HER2 ADC) PRESENTED AT 2025 ASCO ANNUAL MEETING
2025.05.27
首页
上一页
1
2
3
4
5
6
...
55
尾页
下一页